From the Departments of Medicine and Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Center, New York, NY.
A tumor-specific, bcr-abl-derived fusion peptide vaccine can be safely administered to patients with chronic myelogenous leukemia (CML) and can elicit a bcr-abl peptide-specific T-cell immune response. In the present phase 2 trial, 14 patients with CML in chronic phase were vaccinated with 6 fusion peptides mixed with Quillaja saponaria (QS-21). No significant toxic effects were observed. In 14 of 14 patients, delayed-type hypersensitivity (DTH) and/or CD4 proliferative responses developed after beginning vaccinations, and 11 of 14 patients showed interferon-gamma (IFN-gamma) release by CD4 enzyme-linked immunospot (ELISPOT) at one or more time points. These responses were CD4+CD45RO+. A peptide-specific CD8+ interferon-gamma ELISPOT was found in 4 patients. Four patients in hematologic remission had a decrease in Philadelphia chromosome (Ph) percentage (3 concurrently receiving interferon-alpha and 1 on imatinib mesylate), and 3 patients in molecular relapse after allogenic transplantation became transiently polymerase chain reaction (PCR) negative after vaccination; 2 of these patients received concurrent donor lymphocyte infusion (DLI). All 5 patients on IFN-alpha ultimately reached a complete cytogenetic remission. In conclusion, a tumor-specific bcr-abl breakpoint peptide-derived vaccine can be safely administered and can reliably elicit measurable peptide-specific CD4 immune responses, including in patients after bone marrow transplantation, on interferon, or on imatinib mesylate. A relationship between the clinical responses and vaccination cannot be determined from this trial. (Blood. 2004;103:1037-1042)
17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated constitutively activated KIT protein in human mast cells
A potential therapeutic role for small nonpeptidyl compounds that mimic human granulocyte colony-stimulating factor
Activated Fps/Fes partially rescues the in vivo developmental potential of Flk1-deficient vascular progenitor cells
Activated Fps/Fes to the rescue
Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning
An amino acid polymorphism in von Willebrand factor correlates with increased susceptibility to proteolysis by ADAMTS13
Assessment of removal of human cytomegalovirus from blood components by leukocyte depletion filters using real-time quantitative PCR
Association of CD26 with CD45RA outside lipid rafts attenuates cord blood T-cell activation
Bifunctional role for VEGF-induced heme oxygenase-1 in vivo: induction of angiogenesis and inhibition of leukocytic infiltration
Blood plasmacytoid dendritic cell responses to CpG oligodeoxynucleotides are impaired in human newborns